U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07297563) titled 'Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)' on Nov. 21.
Brief Summary: This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Treatment
Intervention:
DRUG: Rituximab
All subjects were randomly assigned to group A (active comparator) and group B (experiment...